Cantor Fitzgerald Starts AmSurg (AMSG) at Hold; Growth Slowed, Outlook Remains Uncertain
Get Alerts AMSG Hot Sheet
Price: $67.75 --0%
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Cantor Fitzgerald initiates coverage on AmSurg (NASDAQ: AMSG) with a Hold. PT $26.00.
Analyst, Joseph D. France, said, "The stock is currently valued near the mid-point of its historical trading range, but while utilization has stabilized, the extent of the market's recovery is unclear, and the company is in the early stages of integrating the National Surgical Care acquisition, which closed 9/1/11...Medicare rates have improved, but the elimination of copayments for colonoscopies has not provided the hoped-for lift...Acquisition opportunities could help offset slow organic growth."
For an analyst ratings summary and ratings history on AmSurg click here. For more ratings news on AmSurg click here.
Shares of AmSurg closed at $25.07 yesterday.
Analyst, Joseph D. France, said, "The stock is currently valued near the mid-point of its historical trading range, but while utilization has stabilized, the extent of the market's recovery is unclear, and the company is in the early stages of integrating the National Surgical Care acquisition, which closed 9/1/11...Medicare rates have improved, but the elimination of copayments for colonoscopies has not provided the hoped-for lift...Acquisition opportunities could help offset slow organic growth."
For an analyst ratings summary and ratings history on AmSurg click here. For more ratings news on AmSurg click here.
Shares of AmSurg closed at $25.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Downgrades Caledonia Mining Corporation (CMCL) to Hold
- UBS Starts Engene Holdings Inc. (ENGN) at Buy
- Truist Securities Starts Merus N.V. (MRUS) at Buy, 'there is more upside on Peto's 2 clinical catalysts'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!